000120060 001__ 120060
000120060 005__ 20240319081012.0
000120060 0247_ $$2doi$$a10.1111/dth.15879
000120060 0248_ $$2sideral$$a130827
000120060 037__ $$aART-2022-130827
000120060 041__ $$aeng
000120060 100__ $$aGarcía-Gil, Miguel Fernando$$uUniversidad de Zaragoza
000120060 245__ $$aFully home-based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study
000120060 260__ $$c2022
000120060 5060_ $$aAccess copy available to the general public$$fUnrestricted
000120060 5203_ $$aMethyl aminolevulinate daylight photodynamic therapy (MAL DL-PDT) is highly effi-cacious for the treatment of nonhyperkeratotic actinic keratosis (AK), even when par-tially performed at home. To evaluate the long-term effectiveness, safety, andpatient-reported outcomes of MAL DL-PDT performed completely by the patient inreal life conditions. An open prospective study was conducted in Spain amongpatients diagnosed with at least five AK lesions on the face or the scalp. Patientsreceived instruction and information in infographic format to perform MAL DL-PDTat home. All had been treated with 30% urea daily for 7 days before the day of MALDL-PDT. Meteorological conditions on the day of the treatment and adverse effectswere recorded. Patients underwent follow-up, and a second session of home-basedMAL DL-PDT if deemed necessary, 3, 6, and 12 months after the initial treatmentsession. The study population consisted of 22 patients (19 men and three women,mean [standard deviation, SD] age, 72.05 [6.96] years). A complete response wasobserved in 47.7% of AK lesions at 3 months (p< 0.001) and 65.9% (n=199) at12 months (p< 0.001). Olsen grade II lesions showed the highest rate of response(76.07% at 12 months). The mean (SD) actinic keratosis area and severity index scoredecreased significantly from 4.99 (2.43) at baseline to 2.33 (1.01) at 12 months(p=0.0234). Adverse effects were mild and expected. A majority of patients were“satisfied”or“very satisfied”with the treatment instruction provided (90.9%) andthe treatment outcome (72.7%). MAL DL-PDT can be applied at home like any othertopical treatment for AK. Our results indicate good long-term effectiveness, a highlevel of patient satisfaction, and no significant side effects
000120060 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000120060 590__ $$a3.6$$b2022
000120060 592__ $$a0.667$$b2022
000120060 591__ $$aDERMATOLOGY$$b16 / 70 = 0.229$$c2022$$dQ1$$eT1
000120060 593__ $$aDermatology$$c2022$$dQ1
000120060 593__ $$aMedicine (miscellaneous)$$c2022$$dQ2
000120060 594__ $$a4.7$$b2022
000120060 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000120060 700__ $$aGracia-Cazaña, Tamara$$uUniversidad de Zaragoza
000120060 700__ $$aCerro-Muñoz, Paulina
000120060 700__ $$aBernal-Masferrer, Laura
000120060 700__ $$aNavarro-Bielsa, Alba$$uUniversidad de Zaragoza
000120060 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Yolanda$$uUniversidad de Zaragoza
000120060 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000120060 773__ $$g35, 11 (2022), e15879 [4 pp.]$$pDermatologic Therapy$$tDermatologic Therapy$$x1396-0296
000120060 8564_ $$s905702$$uhttps://zaguan.unizar.es/record/120060/files/texto_completo.pdf$$yVersión publicada
000120060 8564_ $$s1947485$$uhttps://zaguan.unizar.es/record/120060/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000120060 909CO $$ooai:zaguan.unizar.es:120060$$particulos$$pdriver
000120060 951__ $$a2024-03-18-15:13:48
000120060 980__ $$aARTICLE